Authors:
Golla Nagesh Babu REQUIMTE, Departamento de Química-Fisica, Faculdade de Farmácia, Universidade do Porto, Porto, Portugal
Department of Neurology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India
REQUIMTE, Departamento de Química-Fisica, Faculdade de Farmácia, Universidade do Porto, Rua Aníbal Cunha, 164, 4099-030, Porto, Portugal

Search for other papers by Golla Nagesh Babu in
Current site
Google Scholar
PubMed
Close
,
Alok Kumar Department of Neurology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India

Search for other papers by Alok Kumar in
Current site
Google Scholar
PubMed
Close
,
Jayantee Kalita Department of Neurology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India

Search for other papers by Jayantee Kalita in
Current site
Google Scholar
PubMed
Close
, and
U. K. Misra Department of Neurology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India

Search for other papers by U. K. Misra in
Current site
Google Scholar
PubMed
Close
Restricted access

Abstract

Background: Amyotrophic lateral sclerosis (ALS) is a degenerative disease characterized by progressive depletion of motor neurons in brain, brain stem, and spinal cord, whereas Hirayama disease (HD) results from anterior horn cell loss in the lower cervical cord. On the other hand, matrix metalloproteinases (MMPs) are known to digest components of the extracellular matrix. Of these, MMP-9 is considered as a marker of neuroinflammation. Materials and methods: We have measured MMP-9 levels in the serum of 30 patients with ALS, 10 patients of HD, and 25 healthy controls using ELISA method. Results: MMP-9 levels were significantly elevated in the patients suffering from ALS (P < 0.01) and HD (P < 0.05). Furthermore, MMP-9 levels in ALS have a significant positive correlation (R2 = 0.9) with the duration of the disease. Conclusions: These results suggest that neuroinflammation is an underlying component in ALS pathology and further opens up the search for suitable biomarkers.

  • [1]. P. Corcia H. F. Jafari-Schluep D. Lardillie et al.2003 A clustering of conjugal amyotrophic lateral sclerosis in southeastern France Arch. Neurol. 60 553557.

    • Search Google Scholar
    • Export Citation
  • [2]. A. C. Ludolph J. Hugon M. P. Dwivedi et al.1987 Studies on the aetiology and pathogenesis of motor neuron diseases. Lathyrism: clinical findings in established cases Brain 110 149165.

    • Search Google Scholar
    • Export Citation
  • [3]. R. C. Brown A. H. Lockwood B. R. Sonawane 2005 Neurodegenerative diseases: an overview of environmental risk factors Environ. Health Perspect. 113 12501256.

    • Search Google Scholar
    • Export Citation
  • [4]. P. R. Heath P. J. Shaw 2002 Update on the glutamatergic neurotransmitter system and the role of excitotoxicity in amyotrophic lateral sclerosis Muscle Nerve 26 438458.

    • Search Google Scholar
    • Export Citation
  • [5]. U. K. Misra J. Kalita V. N. Mishra et al.2005 A clinical, magnetic resonance imaging and survival motor neuron gene deletion study of Hirayama disease Arch. Neurol. 62 120123.

    • Search Google Scholar
    • Export Citation
  • [6]. S. Ito S. Kuwabara T. Fukutake et al.2005 HyperIgEaemia in patients with juvenile muscular atrophy of the distal upper extremity (Hirayama disease) J. Neurol. Neurosurg. Psychiatr. 76 132134.

    • Search Google Scholar
    • Export Citation
  • [7]. B. W. Ennis L. M. Matrisian 1994 Matrix degrading metalloproteinases J. Neuro. Oncol. 18 105109.

  • [8]. G. P. Lim J. R. Backstrom M. J. Cullen et al.1996 Matrix metalloproteinases in the neocortex and spinal cord of amyotrophic lateral sclerosis patients J. Neurochem. 67 251259.

    • Search Google Scholar
    • Export Citation
  • [9]. W. M. Beuche M. Yushchenko M. Mader et al.2000 Matrix metalloproteinase-9 is elevated in serum of patients with amyotrophic lateral sclerosis NeuroReport 11 34193422.

    • Search Google Scholar
    • Export Citation
  • [10]. S. Lorenzl S. Narr B. Angele et al.2006 The matrix metalloproteinases inhibitor Ro 26-2853 extends survival in transgenic ALS mice Exp. Neurol. 200 166171.

    • Search Google Scholar
    • Export Citation
  • [11]. S. Lorenzl G. De Pasquale A. Z. Segal et al.2003 Dysregulation of the levels of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the early phase of cerebral ischemia Stroke 34 3738.

    • Search Google Scholar
    • Export Citation
  • [12]. B.G. Schoser D. Blottner 1999 Matrix metalloproteinases MMP-2, MMP-7 and MMP-9 in denervated human muscle NeuroReport. 10 27952797.

    • Search Google Scholar
    • Export Citation
  • [13]. M. Demestre M. Orth G. M. Wells et al.2005 Characterization of matrix metalloproteinases in denervated muscle Neuropathol. Appl. Neurobiol. 31 545555.

    • Search Google Scholar
    • Export Citation
  • [14]. B. R. Brooks 1994 El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial “Clinical limits of amyotrophic lateral sclerosis” workshop contributors J. Neurol. Sci. 124 96107.

    • Search Google Scholar
    • Export Citation
  • [15]. F. H. Norris Jr. P. R. Calanchini R. J. Fallat et al.1974 The administration of guanidine in amyotrophic lateral sclerosis Neurology 24 721728.

    • Search Google Scholar
    • Export Citation
  • [16]. K. Mahmoud K. Khatuna Y. C. Noel et al.2007 Matrix metalloproteinase-9 regulates TNF-α and FasL expression in neuronal, glial cells and its absence extends life in a transgenic mouse model of amyotrophic lateral sclerosis Exp. Neurol. 205 7481.

    • Search Google Scholar
    • Export Citation
  • [17]. M. Kiaei S. Petri K. Kipiani et al.2006 Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis J. Neurosci. 26 24672473.

    • Search Google Scholar
    • Export Citation
  • Collapse
  • Expand

Clinical and Experimental Medical Journal
Language English
Size  
Year of
Foundation
2007
Publication
Programme
ceased
Volumes
per Year
 
Issues
per Year
 
Publisher Akadémiai Kiadó
Publisher's
Address
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245
Responsible
Publisher
Chief Executive Officer, Akadémiai Kiadó
ISSN 2060-6249 (Print)
ISSN 2060-968X (Online)

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Nov 2023 7 2 0
Dec 2023 19 0 1
Jan 2024 8 1 1
Feb 2024 10 0 0
Mar 2024 5 0 0
Apr 2024 22 0 0
May 2024 0 0 0